<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01100463</url>
  </required_header>
  <id_info>
    <org_study_id>OIC-1UO-C001</org_study_id>
    <nct_id>NCT01100463</nct_id>
  </id_info>
  <brief_title>Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome</brief_title>
  <official_title>A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Topical Cream (UTC) in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanometics (d.b.a. PHD Biosciences)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanometics (d.b.a. PHD Biosciences)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to see if combining uracil cream (UTC) with
      capecitabine (Xeloda) can prevent Hand-Foot Syndrome. The study will also see what effects
      UTC and capecitabine may have in patients with metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Capecitabine is used in the treatment of human breast cancer among other human cancers.
      Following absorption, capecitabine is converted enzymatically to 5-fluorouracil (5-FU). The
      administration of capecitabine or 5-FU can cause a cutaneous toxicity known as hand-foot
      syndrome (HFS) or palmar-plantar erythrodysesthesia (PPE). HFS is progressive with dose and
      duration of exposure to 5-FU or capecitabine. HFS is characterized by progressive redness and
      cracking of hands and feet. Currently, there are no approved therapies for HFS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Grade 2 and 3 HFS as graded by Roche Criteria</measure>
    <time_frame>Maximum of 6 months of therapy</time_frame>
    <description>Time to first HFS event
Requirements for capecitabine dose reduction/interruption due to HFS
Digital Photos will be taken of the hands and feet at specific intervals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Pharmacokinetic Levels of Uracil will be drawn</measure>
    <time_frame>Maximum of 6 months of therapy</time_frame>
    <description>Pharmacokinetic levels will be drawn at specific intervals</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-Tumor efficacy of Capecitabine</measure>
    <time_frame>Maximum of 6 months of therapy</time_frame>
    <description>RECIST - Radiologic Criteria for subjects with measurable disease</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Palmar-Plantar Erythrodysesthesia</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo Lotion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1% Uracil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cream</intervention_name>
    <description>Twice daily lotion to prevent HFS</description>
    <arm_group_label>Placebo Lotion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1% Uracil Cream</intervention_name>
    <description>Twice daily lotion to prevent HFS</description>
    <arm_group_label>0.1% Uracil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females, at least 18 years old

          -  Histologically or cytologically confirmed metastatic breast cancer

          -  You also cannot have any ulcerations or open wounds on palms of hands or soles of feet

        Exclusion Criteria:

          -  Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for
             nitrosoureas or mitomycin C)prior to entering the study or if you have not recovered
             to Grade 1 or better (except for alopecia)from adverse events due to agents
             administered more than 2 weeks earlier.

          -  Use vitamin 6, chronic use of Cox-2 inhibitors, use full-dose anti- coagulants or use
             nicotine patches.

        The above is not a complete list of eligibility criteria. Please see your study doctor for
        more information.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Cantrell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Birmingham Hematology/Oncology Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bruno Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Deaconess Clinic</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Centers</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Signal Point Clinical Research Center</name>
      <address>
        <city>Middleton</city>
        <state>Ohio</state>
        <zip>45042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 6, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2010</study_first_posted>
  <last_update_submitted>October 5, 2019</last_update_submitted>
  <last_update_submitted_qc>October 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HFS, Hand-Foot Syndrome, Capecitabine, Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Hand-Foot Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

